P-Cure

P-Cure has developed a proprietary, imaging-based solution for cost-effective cancer treatment using proton radiation. The companys delivery system enables the use of inexpensive fixed-beam technologies for the treatment of all cancer indications. The P-Cure system aims to improve treatment accuracy, expand the number of new indications, and shorten the length of treatment procedures. The system is compatible with existing accelerators, beam lines, and treatment protocols. The P-ARTIS is a comprehensive and fully integrated solution to treat patients with protons. It includes diagnostic-quality volumetric imaging, a robotic positioning system, patient support systems, real-time X-ray imaging, operating panels, and workstations. The P-ARTIS 4D volumetric imaging system is equipped with the Brilliance Big Bore CT integrated into the sliding system. The setup enables patients to be scanned in the treatment position while being kept stationary.

P-Cure has raised $36M in total funding across 4 rounds. The company is currently at the B stage. Key investors include Popular Line Medical, StarVest Partners, Lions Peak Capital.

P-Cure was founded in 2007 by Michael Marash (Founder & CEO).

P-Cure operates in Health Tech & Life Sciences, Medical Devices, Medical Treatment & Therapeutics, with core technologies in Machinery & Robotics, Platforms & Interfaces, Software. Target customers: Healthcare & Life Sciences, Healthcare, Providers, Medical Devices Industry, Medical Equipment.

P-Cure is based in Shilat, Israel, Center District. The company also has offices abroad.